Engineered aldolase for the fermentative production of L-fucose and other rare sugars.

Information

  • Research Project
  • 8979634
  • ApplicationId
    8979634
  • Core Project Number
    R43GM116270
  • Full Project Number
    1R43GM116270-01
  • Serial Number
    116270
  • FOA Number
    PA-14-071
  • Sub Project Id
  • Project Start Date
    3/1/2016 - 8 years ago
  • Project End Date
    1/31/2017 - 7 years ago
  • Program Officer Name
    MARINO, PAMELA
  • Budget Start Date
    3/1/2016 - 8 years ago
  • Budget End Date
    1/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    01
  • Suffix
  • Award Notice Date
    2/25/2016 - 8 years ago
Organizations

Engineered aldolase for the fermentative production of L-fucose and other rare sugars.

? DESCRIPTION (provided by applicant): The goal of this proposal is to develop a fermentative strategy for the large-scale production of L-fucose and other rare sugars. L-fucose (6-deoxy-L-galactose) is an important hexose deoxysugar found in a variety of organisms attached to an array of macromolecules. These L-fucose containing glycans exhibit a wide range of medicinal properties including supporting infant health (L-fucose containing human milk oligosaccharides); anticoagulant and antithrombotic, antivirus, antitumor, anticancer and immunomodulatory, anti-inflammatory, blood lipids reducing, antioxidant, activitiy against hepatopathy, uropathy and renalpathy, gastric protective effects and therapeutic potential in surgery (L-fucose containing polymers). The L-fucose monomer has therapeutic properties such as inhibiting virulence factors and is also an invaluable synthetic starting material for a wide range of molecules including human milk oligosaccharides, blood group antigens, E and P-selectin antagonists, and functionalized L-fucose derivatives. In addition to pharmaceutical relevance, L-fucose also possesses topical properties attractive to the cosmetic industry including anti-aging, wrinkle reducing and is safe for sensitive skin. Despite the impressive range of bioactivity discovered thus far, L-fucose remains prohibitively expensive and unavailable in the scale needed to support these applications. We feel a fermentative approach is needed to meet these large-scale requirements and to provide the glycoresearch community with this important building block needed to prepare scarce or unavailable glycans. A key aspect of our strategy is the production of an engineered L-fuculose-1-phosphate aldolase that no longer requires the phosphorylated donor substrate, dihydroxyacetone phosphate. Instead, the novel L-fuculose-1-phosphate aldolase (FucA) will catalyze the condensation between dihydroxyacetone and L-lactaldehyde to form L-fuculose, thereby bypassing the typical sugar-phosphate intermediate. Through metabolic engineering, we envision an E. coli system capable of integrating this engineered L-fuculose-1-phosphate for the specific synthesis of L-fucose. In Phase I we will demonstrate the feasibility of a fermentative L-fucose system by identifying and engineering a mutant FucA enzyme capable of condensing dihydroxyacetone and L-lactaldehyde to form L-fuculose for the ultimate production of L-fucose. In Phase II we will focus on the genetic and metabolic engineering of E. coli for the production and accumulation of the substrates needed for the engineered L-fuculose-1-phospahte aldolase. We propose a yield of 50-100 g/L production of L-fucose after integration of the engineered L-fuculose-1-phosphate aldolase and subsequent optimizations. In Phase III we will commercialize L-fucose as well as other rare sugars produced by the engineered L-fuculose-1-phosphate aldolase using various acceptor aldehyde substrates.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    175813
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:175813\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZUCHEM, INC.
  • Organization Department
  • Organization DUNS
    126677041
  • Organization City
    CHICAGO
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    606124814
  • Organization District
    UNITED STATES